Merck, Moderna Phase 3 Combo Cuts Melanoma Recurrence Risk 42%
Merck said intismeran (V940) plus KEYTRUDA reduced recurrence or death risk by 42% and distant metastasis or death risk by 38% versus KEYTRUDA alone in resected stage IIB–IV melanoma. Overall survival data are not mature; the companies are engaging regulators.
Merck said the Phase 3 INTerpath-001 study found that intismeran (V940) combined with KEYTRUDA reduced the risk of recurrence or death by 42% and the risk of distant metastasis or death by 38%, compared with KEYTRUDA alone, in patients with resected stage IIB—IV melanoma. Overall survival data are not mature. The companies are engaging with regulators.